The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression

被引:194
|
作者
Burnstock, Geoffrey [1 ,2 ,3 ]
Knight, Gillian E. [1 ]
机构
[1] UCL, Sch Med, Auton Neurosci Ctr, Rowland Hill St, London NW3 2PF, England
[2] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia
[3] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia
关键词
Pain; Infection; Cancer; CNS disorders; Cardiovascular; Airways; Diabetes; Kidney; Bladder; Liver; Gut; Immune cells; BRILLIANT BLUE G; TYPE-2; DIABETIC-RATS; P2X(7) RECEPTOR; PURINERGIC RECEPTORS; EXTRACELLULAR ATP; MOUSE MODEL; NLRP3; INFLAMMASOME; IN-VIVO; CELL INVASION; ANIMAL-MODEL;
D O I
10.1007/s11302-017-9593-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Seven P2X ion channel nucleotide receptor subtypes have been cloned and characterised. P2X7 receptors (P2X7R) are unusual in that there are extra amino acids in the intracellular C terminus. Low concentrations of ATP open cation channels sometimes leading to cell proliferation, whereas high concentrations of ATP open large pores that release inflammatory cytokines and can lead to apoptotic cell death. Since many diseases involve inflammation and immune responses, and the P2X7R regulates inflammation, there has been recent interest in the pathophysiological roles of P2X7R and the potential of P2X7R antagonists to treat a variety of diseases. These include neurodegenerative diseases, psychiatric disorders, epilepsy and a number of diseases of peripheral organs, including the cardiovascular, airways, kidney, liver, bladder, skin and musculoskeletal. The potential of P2X7R drugs to treat tumour progression is discussed.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 50 条
  • [31] Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases
    Zheng, Huiyong
    Liu, Qiang
    Zhou, Siwei
    Luo, Hongliang
    Zhang, Wenjun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [32] P2X7 receptors and klotho
    Unwin, Robert
    PURINERGIC SIGNALLING, 2020, 16 (02) : 151 - 152
  • [33] Editorial: P2X7 as Common Therapeutic Target in Brain Diseases
    Engel, Tobias
    Nicke, Annette
    Deussing, Jan M.
    Sperlagh, Beata
    Diaz-Hernandez, Miguel
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2021, 14
  • [34] P2X7 Receptor as a Potential Target for Major Depressive Disorder
    Huang, Zeyi
    Tan, Sijie
    CURRENT DRUG TARGETS, 2021, 22 (10) : 1108 - 1120
  • [35] P2X7 receptor as a potential therapeutic target for perinatal brain injury associated with preterm birth
    Zucker, Emily
    Burd, Irina
    EXPERIMENTAL NEUROLOGY, 2022, 357
  • [36] The potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target?
    Pacheco, Paulo A. F.
    Faria, Robson X.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2021, 93 (02)
  • [37] P2X7 as a potential target in age related macular degeneration
    Fletcher, Erica L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [38] P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment
    Brisson, Lucie
    Chadet, Stephanie
    Lopez-Charcas, Osbaldo
    Jelassi, Bilel
    Ternant, David
    Chamouton, Julie
    Lerondel, Stephanie
    Le Pape, Alain
    Couillin, Isabelle
    Gombault, Aurelie
    Trovero, Fabrice
    Chevalier, Stephan
    Besson, Pierre
    Jiang, Lin-Hua
    Roger, Sebastien
    CANCERS, 2020, 12 (09) : 1 - 23
  • [39] The role of P2X7 in pain and inflammation
    Hughes, Jane P.
    Hatcher, Jonathan P.
    Chessell, Iain P.
    PURINERGIC SIGNALLING, 2007, 3 (1-2) : 163 - 169
  • [40] Transcriptional regulation and therapeutic targeting of P2X7 receptors in diabetic nephropathy
    Menzies, Robert I.
    Booth, John W.
    Mullins, John J.
    Bailey, Matthew A.
    Tam, Frederick W.
    Norman, Jill T.
    Unwin, Robert J.
    FASEB JOURNAL, 2017, 31